References

1. Grossman HB, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med. 2003;349:859-66

2. Malstrm P-U, Rintala E, Walhqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I. J Urol. 1996;155:1903-6

3. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354:533-40

4. International Collaboration of Trialists1; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of theBA06 30894 trial J Clin Oncol.2011 Jun 1;29(16):2171-7

5. Advanced Bladder Cancer Overview Collaboration. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urol. 1995;75:206-13

6. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927-34

7. Singapore Cancer Registry Report No. 7. Trends in Cancer Incidence in Singapore 1968-2007. Health Promotion Board Singapore.

8. Booth CM, Siemens DR, Li G et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer 2014;120:1630-8

9. Sternberg CN, de Mulder P, Schornagel JH, et al on behalf of EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-4

10. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20;23:4602-8.

11. Stevenson SM, Danzig MR, Ghandour RA, et al. Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Urol Oncol. 2014 Jul 3. pii: S1078-1439(14)00164-1. doi: 10.1016/j.urolonc.2014.05.001. [Epub ahead of print]

12. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991;145:459-67.

13. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial. J Urol 1994;152:81-4.

14. Stckle M, Wellek S, Meyenburg W, et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: Prognostic impact of lymph node involvement. Urology 1996;48:868-75.

15. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-500.

16. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:189-199

17. Booth CM, Tannock IF. Adjuvant chemotherapy for bladder cancer provides benefit to patients: convergence of evidence despite lack of level 1 data. (Manuscript in submission)

18. Sternberg CN, Skoneczna IA, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Lancet Oncol 2015;16:76-86

19. Bellmunt J, Orsola A, Wiegel T, et al. on behalf of the ESMO Guidelines Working Group. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2011;22 (Supplement 6): vi45vi49